MET and non-small cell lung carcinoma: ,2 There are numerous oncogenic driver genomic alterations in advanced NSCLC that have established clinical utility to guide treatment decisions, including EGFR mutations, ERBB2 activating alterations, ALK rearrangements, ROS1 rearrangements, BRAF mutations, KRAS mutations, RET rearrangements, MET exon 14 skipping mutations, NTRK1/2/3 gene fusions.3-5